The improved survival observed with abiraterone acetate 1,2 or enzalutamide 3,4 in patients with metastatic castration-resistant prostate cancer (mCRPC) who experience disease progression despite conventional androgen-deprivation therapy (ADT) validates the androgen receptor (AR) as a viable target in this group of patients. Yet many questions remain, particularly in light of the so-called bookends of the published clinical data that lead to the approval of these drugs. On one end of the spectrum, the fairly remarkable success that has been observed with these agents has been paired with the equally sobering realization that the development of resistance to these agents is nearly universal and is often associated with the development of a highly aggressive phenotype with rapidly progressive, fatal disease, for which few viable therapeutic options exist. At the other end of the spectrum, investigators have been pushing the envelope to use these active agents in earlier disease states, where disease burden is lower, patients are less heavily pretreated, and potentially, a broader therapeutic index can be exploited. In the article that accompanies this editorial, Taplin et al 5 report the results of a phase II clinical trial of preprostatectomy (neoadjuvant) abiraterone acetate. Although the results of this trial do not support the use of this approach as a standard of care, they provide important insights into the questions at both ends of the therapeutic spectrum.
For many cancer types, the development of systemic therapy for high-risk localized disease has been predicated on a potential impact on both local and micrometastatic disease control. In the case of localized prostate cancer, there is every reason to believe that neoadjuvant ADT should be of utility. First, a cohort of patients with a high risk of recurrence can be readily identified, 6, 7 so enrichment strategies that result in a more robust activity signal can be developed. Second, oncogenesis and disease progression is deeply dependent on a single signaling pathway, the AR, with the vast majority of cancers relying on this pathway for growth and survival. Third, the pathway can be effectively and easily pharmacologically targeted. Fourth, there is ample evidence that inhibition of the specific pathway is sufficient to halt the neoplastic phenotype. Finally, this approach has been extensively tested and validated in patients with advanced disease, for whom ADT is the standard of care, and widely used because of its significant palliative and life-prolonging effects. On the basis of these observations, the utility of neoadjuvant (preprostatectomy) ADT has been extensively explored. [8] [9] [10] [11] [12] [13] [14] [15] Surprisingly, although several series demonstrated a reduction in the rate of positive surgical margins, in no patient has this observation translated into an improvement in prostate-specific antigen (PSA) -progression-free survival, a generally accepted intermediate outcome end point, 7 nor has a survival advantage been demonstrated for this approach. Consequently, neoadjuvant ADT is neither widely used nor recommended in treatment guidelines and algorithms, with National Comprehensive Cancer Network guidelines specifically indicating that, "Neoadjuvant ADT for RP [radical prostatectomy] is strongly discouraged." 16(p698) Why has neoadjuvant ADT failed to demonstrate clinical benefit in patients with localized prostate cancer? It is possible that localized prostate cancer is simply not as uniformly and exquisitely dependent on androgens as mediators of transcriptional activity as anticipated. Stated another way, there might exist prostate cancer cells, even at this early stage of disease, that are resistant to ADT. Whether such resistance is innate or adaptive in response to the selective pressure of therapy is an important and unresolved question. Alternatively, it has been postulated that the problem lies not in a lack of sensitivity to ADT, but rather in inadequate androgen deprivation itself. 17 These hypotheses can each be tested. The former-that there exist clones of cells that are not sensitive to ADT-is being prospectively tested by the Cancer and Leukemia Group B (CALGB [Alliance]) study 90203, an intergroup trial randomly assigning men with high-risk localized prostate cancer to neoadjuvant ADT plus docetaxel followed by radical prostatectomy versus immediate prostatectomy with no neoadjuvant therapy. 18 The second premise: that conventional ADT is inadequate and results in incomplete tissue suppression of androgens, which in turn results in incomplete tumor killing, is the hypothesis addressed by Taplin et al. 5 This hypothesis was put forth by Mostaghel et al, 17 who had previously demonstrated that so-called standard ADT inadequately suppressed androgen-regulated gene expression, and suggested that ablation or reduction of circulating androgens was not necessarily reflective of androgen ablation within the prostate itself.
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Taplin et al 5 turned to abiraterone acetate as a means of achieving more intense androgen deprivation in the neoadjuvant setting. Abiraterone acetate prolongs survival in patients with mCRPC, and therefore seems to be an appropriate agent to test in earlier stages of the disease. Abiraterone acetate is a prodrug for abiraterone, a CYP17 inhibitor, which has the capacity to lower serum testosterone levels to less than 1 ng/dL (compared with levels closer to 20 ng/dL that are achieved with conventional ADT). 19 The premise that underpinned the use of abiraterone in this trial was that it would decrease intraprostatic androgen levels, which would translate to decreased AR transcriptional activity, and in turn to clinical benefit. Patients with intermediate-to high-risk localized prostate cancer were randomly assigned to 12 weeks of systemic ADT (with a luteinizing hormonereleasing hormone agonist [LHRHa]) alone, or with the addition of abiraterone, before measuring tissue androgen levels in biopsies. Subsequently, all patients received an additional 12 weeks of combination LHRHa plus abiraterone therapy before undergoing radical prostatectomy. This approach allowed two comparisons: the primary planned analysis comparing two concurrently treated, randomly assigned cohorts, and a sequential cohort in which every patient who started out on LHRHa alone served as his own control when he underwent cross-over and abiraterone was added to his regimen. The primary end point of this study was pharmacodynamic-the impact (at 12 weeks) on tissue levels of testosterone and dihydrotestosterone. Notably, the randomized and sequential data regarding hormone levels were internally consistent, providing confidence in the data, and furthermore suggesting that in the future, biopsies to determine tissue hormone levels can be used in lieu of full prostatectomy specimens. It is important to note that this study was not designed to test the clinical benefit of this approach, nor was it powered to detect differences in clinical or pathologic outcomes. In addition, the use of a cross-over design confounds the pathologic data, which reflect either 12 or 24 weeks of abiraterone, but does not allow a comparison with a control group of patients receiving no abiraterone therapy.
The study met its primary goal, in that the addition of abiraterone acetate to LHRHa, whether evaluated as part of the randomized design of the trial or as the cross-over design, resulted in deeper suppression of androgen levels. Relative to LHRHa alone, the addition of abiraterone resulted in an 85% decline in dihydrotestosterone (DHT) levels, a 97% to 98% decline in dehydroepiandrosterone (DHEA) levels, and a 77% to 78% decline in androstenedione levels. Interestingly, testosterone tissue levels decreased only half as much as DHEA and androstenedione, with a 38% decline in the randomized data and a 43% decline in the sequential cross-over data. Because testosterone is a downstream metabolite of DHEA and androstenedione, the implications of a more modest decline in testosterone are unclear. Furthermore, serum PSA levels, putatively a marker of AR transcriptional activity, were 10-fold lower at 12 weeks in the patients receiving abiraterone (0.1 ng/mL v 1.06 ng/mL). This study also confirmed previous observations that serum androgen levels do not accurately reflect tissue androgen levels. The addition of abiraterone acetate led to discordant declines in hormone levels in the serum versus tissue compartments. Thus, the percent decline in androstenedione and DHEA levels was roughly comparable in serum and in tissue. However, serum testosterone levels declined with abiraterone by 61% to 69%, whereas tissue testosterone levels declined less (38% to 43%). Most notably, the addition of abiraterone led to a marked decline in DHT tissue levels of 85%, yet serum DHT levels were in fact 12% higher when the randomized data were considered, and only 6% lower when the sequential data were evaluated. Thus, other than using serum testosterone levels as a global measure of ongoing androgen deprivation, there is no justification for the clinical practice of measuring serum hormone levels, including DHT and adrenal androgens, as some measure of efficacy of therapy.
The authors are to be commended for taking on the methodologic morass surrounding the lack of consensus criteria for response evaluation in the neoadjuvant setting. They prospectively applied two novel definitions for minimal residual disease (MRD), one derived from reconstructed whole cross-sectional slices, and the other from a three-dimensional estimate of residual cancer burden, which was calculated as the volume of tumor corrected by tumor cellularity. The novel reporting of combined pathologic CR (pCR) plus MRDsomewhat akin to an overall objective response rate being comprised of complete responses plus partial responses-was 62% for the patients receiving 24 weeks of abiraterone compared with 48% for those receiving 12 weeks of abiraterone. Although provocative, these end points are not validated, and there were differences in results when central review was required, raising questions about reproducibility and broad applicability. Unfortunately, the improved pathologic results with 24 weeks of therapy (with regard to pCR/MRD) were not mirrored in more conventional pathologic findings with clearer links to clinical outcome, such as lymph node positivity (24% in the 24-week group compared with 11% in the 12-week group). Thus, although it is tempting to assume the pCR/MRD pathologic outcome variable is linked to clinically significant end points, it would be incorrect to make that assumption. In addition, acknowledging the perils of cross-trial comparisons, the pCR rate reported by Taplin et al 5 (7% overall; 10% in the 24-week abiraterone group) was not dramatically different from previous reports of neoadjuvant therapy. A pCR of 10% was reported by Mostaghel et al 20 when using a combination of neoadjuvant goserelin, bicalutamide, and dutasteride, with an 8% pCR rate when ketoconazole was added to that regimen. Similarly, in a trial of 3 months versus 8 months of preoperative leuprolide plus flutamide, Gleave et al 21 reported that 23 of 247 patients (9.3%) on the longer treatment arm had a pCR compared with 13 of 253 patients (5.1%) treated with 3 months of ADT. Taken together, these data raise the question of whether there is a ceiling to the pCR rate that is a function of the malignancy and not of the therapy used.
One of the more striking results of this study is what neoadjuvant abiraterone therapy did not accomplish, although without a notreatment control, the true impact of the neoadjuvant therapy used cannot be known. Neoadjuvant therapy did not eradicate disease. A large percentage of patients had residual cancer in their radical prostatectomy specimens: the pCR rate was 7%; 54% of patients had a pathologic stage of T3 or higher; 18% had node-positive disease (in fact, the group of patients receiving 24 weeks of abiraterone were more than twice as likely to harbor positive nodes than patients receiving 12 weeks of abiraterone: 24% v 11%); and overall, 14% of patients had positive margins. Taplin et al 5 have begun the important task of interrogating and characterizing this residual cancer to understand the nature of abiraterone-resistant disease. The presence of so-called ARresponsive tissue (using nuclear AR staining and PSA staining as putative markers of AR responsiveness) might argue that the presence of resistant cancer simply reflects inadequate therapy and the need to further optimize the type and duration of neoadjuvant therapy. By contrast, the presence of AR-nonresponsive tissue, in which AR and PSA staining were abrogated, would argue for a non-AR-mediated mechanism, either intrinsic to the cancer or acquired (adaptive) within 24 weeks of therapy. The data are complex. If abrogation of PSA or AR expression is arbitrarily defined as staining that is either absent or involving less than 10% of cells, it is clear that AR and PSA do not track together. There is more AR abrogation than there is PSA abrogation, with nuclear AR staining abrogation in approximately 6% of patients with residual cancer, cytoplasmic AR abrogation in approximately 25% of patients, and more broad PSA abrogation in approximately 75% of patients with residual cancer. Interestingly, the distribution of AR and PSA staining was similar between treatment groups, and it is clear that populations of AR-positive and -negative and/or PSA-positive and -negative cells can coexist within the same patient. Resistant disease with AR pathway abrogation seems to occur in a minority of patients but raises an important question with broad therapeutic implications. Is there a preexistent abiraterone-refractory clone of cells, or does abiraterone-refractory disease arise as a consequence of an adaptive response to exposure to abiraterone?
In summary, targeting the AR in the preprostatectomy setting with abiraterone acetate has a clear biologic effect, decreasing tissue levels of androgens as well as serum PSA levels. However, this effect has not yet been shown to translate into clinical benefit and cannot be considered a standard of care. The early emergence of resistance may in part reflect a pharmacokinetic or pharmacodynamic impediment but may also reflect the emergence of non-AR-mediated resistance to abiraterone. Whether these mechanism(s) are innate or adaptive, and whether the same process is responsible for abiraterone resistance in patients with metastatic CRPC, are important and as yet unanswered questions. The work from Taplin et al 5 is an important contribution toward answering these questions.
